UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2015

Sucampo Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4520 East-West Highway, 3rd Floor Bethesda, Maryland	20814
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On March 10, 2015, Sucampo Pharmaceuticals, Inc. ("Company") will make a corporate update presentation at the 27th Annual ROTH Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the Conference. All meetings will include written communication comprised of slides. The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The corporate update presentation slides dated March 10, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: March 10, 2015

By: /s/ Thomas J. Knapp
Name: Thomas J. Knapp
Title: EVP, Chief Legal Officer and Corporate Secretary

Sucampo Pharmaceuticals, Inc.
2015 ROTH Healthcare Conference

March 10, 2015

Stan Miele
Senior Vice President, Sales & Marketing, President, Sucampo Pharma Americas, LLC

SUCAMPO
The Science of Innovation

Forward-Looking Statements

This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; the ability of Sucampo to develop and commercialize existing and pipeline products; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities Exchange Commission (SEC) on March 9, 2015.

Investment Highlights

- Lead product with differentiated profile in an attractive market with a large unmet need
- Blue chip partnerships provide global reach and drive outsized revenue growth
- Multiple levers available to drive sustainable long term growth
- Robust product pipeline that will build on a strong foundation
- Well-defined lifecycle management strategy maximizes franchise value
- Strong financial performance with robust balance sheet and cash position
- Deep management bench with proven experience in new product development

Clear Strategy to Methodically Build a Leading Bio/Pharma Company



SUCAMPO
The Science of Innovation

Proven and Experienced Management Team

Peter Greenleaf Chief Executive Officer	Histogenics, AstraZeneca, MedImmune, Johnson & Johnson, centocor
Peter Kiener, D.Phil Chief Scientific Officer	Bristol-Myers Squibb, MedImmune, Ambrx, Zyngenia
Peter Lichtlen, M.D., Ph.D. Chief Medical Officer	Alcon, ESBATech
Matthias Alder Executive Vice President, Business Development & Licensing	CYTOS, micromet, NOVARTIS
Max Donley Executive Vice President of Human Resources	AstraZeneca, MedImmune, VIVUS
Steven Caffé, M.D. Senior Vice President, Regulatory Affairs	amag, MedImmune, Baxter, SANOFI, MERCK
Stanley Miele Senior Vice President, Sales & Marketing, President, Sucampo Pharma Americas, LLC	Abbott Diagnostics, MILLENNIUM PHARMACEUTICALS, INC, Abbott Laboratories
Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications	AstraZeneca, MedImmune, Pfizer
Andrew Smith Chief Financial Officer	Biocompatibles, ALLERGAN, clearlab, RETROSCREEN VIROLOGY

Expanded Management Team with Considerable Experience in Product Development and Commercialization

SUCAMPO
The Science of Innovation


amitiza
lubiprostone

AMITIZA is a Unique and Highly-Differentiated Product

- **Most expansive label in constipation market: 3 indications, 3 patient types**
  - **CIC:** Chronic Idiopathic Constipation
  - **IBS-C:** Irritable Bowel Syndrome with Constipation
  - **OIC:** Opioid Induced Constipation in Adults (non-cancer)
- **Most experienced product: over 9M prescriptions since 2006**
- **Only product with a dual mechanism of action**
  1. Increases intestinal fluid secretion
  2. Stimulates recovery of mucosal barrier function
- **Key product characteristics**
  - Locally-acting
  - Rapid and predictable onset of action
- **Well-tolerated product with established safety profile**
  - No black box warning

SUCAMPO
The Science of Innovation

Addressing Large Market with Significant Unmet Need

Market MATTY TRx by Category thru Dec 2014



Brand/Generic MATTY TRx thru Dec 2014



Brand TRx by Category thru Dec 2014



OTC Market: additional ~$800M annually

SUCAMPO
The Science of Innovation

Accelerating Growth is Evidence of Compelling Value Proposition

U.S. (Takeda)



Japan (Abbott)



*Based on Management assumption of 46 capsules per TRx

SUCAMPO
The Science of Innovation

Multiple Levers Will Drive AMITIZA Outsized Growth

SUCAMPO
The Science of Innovation

New Market Opportunities

Global prevalence of constipation disorders ranges from 5-18%



Takeda is #1 GI company world wide
Takeda has rights to all markets except Japan (Mylan) and China

*Successful completion of MRP in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, Netherlands, and Spain; Ireland first to issue National Marketing Authorization

SUCAMPO
The Science of Innovation

AMITIZA Life Cycle Management

Expand AMITIZA franchise through new formulation and new indication

1. New Formulation

- Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients
- Incremental opportunity to address the roughly 40% of adults who have difficulty swallowing pills
- Next step: Phase 3 commence 2H 2015

2. New Pediatric Functional Constipation Indication

- Constipation is one of the most common gastrointestinal complaints in children
- US Prevalence: 18% of pediatric population (13.5M)
- Unmet need: No FDA-approved competition for AMITIZA in pediatric population (black box warning for linaclotide and prucalopride failed in Phase 4)
- Current formulation: older children (6-17 years) who are able to take the current capsule formulation
- Alternate formulation: younger children (6 months and above)

Pipeline

At-A-Glance: Sucampo Pipeline

	CLINICAL FOCUS	STAGE OF CLINICAL DEVELOPMENT					TIMELINE TARGETS	
	LEAD COMPOUNDS	PHASE1	PHASE 2		PHASE 3		NDA/MAA FILING	APPROVAL
Lifecycle Management	Lubiprostone – Pediatric Functional Constipation (6 years-17 years)				Pivotal: LPI – 2H 2015	Open-Label: LPI – 2H 2015	2016*	2017*
Lifecycle Management	Lubiprostone – Alternate Formulation (Adults)				FPI – 2H 2015 LPI – 2H 2015		2H 2016*	2017*
Lifecycle Management	Lubiprostone – Alternate Formulation – Pediatric Functional Constipation (6 months- 6 years)				Pivotal: FPI – 1H 2016 LPI – 1H 2017	Open-Label: FPI – 1H 2016 LPI – 2H 2016	2017*	2018*
Clinical Development	Cobiprostone – Oral Mucositis		FPI – 1H 2015 LPI – 2H 2016		FPI – 2017 LPI – 2018		2018	2019
Clinical Development	Cobiprostone – NERD		FPI – 2H 2014 LPI – 2H 2015		FPI – 2018 LPI – 2018		2020	2021

COMPLETED IN PROGRESS / PROJECTED START

*Pending partner discussions

SUCAMPO The Science of Innovation

Supplementing Existing Pipeline

- Commenced assessment of external programs
- Complement existing product pipeline
- Leverage current skills and experience of Sucampo
- Therapeutic areas
- Platform- and technology- agnostic
- Orphan and specialist products

Financials

Key Facts and Financial Summary

Financial Highlights for Q4 2014	
Cash & Equivalents	$110.0M
Notes Payable	$25.8M
Total Revenue	$37.8M
Net Income	$9.3M
EPS	$0.21
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	$91.1M

Financial Highlights for FY 2014	
Total Revenue	$115.5M
Net Income, excluding special items	$17.9M
EPS, excluding special items	$0.40
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	$331.6M

2015 Financial Guidance	
Net Income	$25M - $30M
EPS	$0.55 - $0.65

Upcoming Milestones

Event	Expected Timing
Global partnership agreement for AMITIZA	√
Updated on AMITIZA alternate formulation and PFC development	√
Filed AMITIZA (CIC and OIC) for approval in Canada	√
Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets	√
Decision made on ion channel activator program for LSS	√
Cobiprostone NERD Ph. 2 FPI	√
Cobiprostone oral mucositis Ph. 2 FPI	1H 2015
Approvals for AMITIZA in additional European markets	
Lubiprostone alternate formulation Ph. 3 FPI	2H 2015
Lubiprostone alternate formulation Ph. 3 LPI	
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (pivotal)	
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (open-label)	
Expected approval of AMITIZA (CIC and OIC) in Canada	
Cobiprostone NERD Ph. 2 LPI	
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (pivotal)	1H 2016
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (open-label)	
File lubiprostone alternate formulation for approval in U.S.	2H 2016
Cobiprostone oral mucositis Ph. 2 LPI	
Lubiprostone PFC (6 months – 6 years) LPI (open-label)	

Investment Highlights

- Lead product with differentiated profile in an attractive market with a large unmet need
- Blue chip partnerships provide global reach and drive outsized revenue growth
- Multiple levers available to drive sustainable long term growth
- Robust product pipeline that will build on a strong foundation
- Well-defined lifecycle management strategy maximizes franchise value
- Strong financial performance with robust balance sheet and cash position
- Deep management bench with proven experience in new product development



Q&A

SUCAMPO
The Science of Innovation